Warm Greetings!!!

Welcome to yet another most pleasant Reading of our newsletter.

It is always my privilege to reach you on the 1st & 17th of every month, for the last 13 years. Please do not hesitate to share your comments on this edition to enable us to constantly improve. Please feel free to get in touch with us. You may find our previous issues on our website jagograhakjago.com or in the NEWS ARCHIVE section of every issue of The Prescription, in case you’ve missed any of them. You may also look us up on Facebook.

Stay Healthy. Stay Protected.
Pyush Misra
Editor-in-Chief

“Achieve access for all women and girls to digital innovations and technologies"

Dr. Poonam Khetrapal Singh
Regional Director,
WHO South-East Asia

June 24, 2023, In order to encourage the sustainable quality in healthcare and patient safety, innovative ideas and implemented practices, the National Accreditation Board for Hospitals and Healthcare Providers Read More...

June 20, 2023, Indian telehealth platforms are working to strengthen their capability on quality accountability and accreditation. When digital health witnesses expansion, telehealth accreditation becomes critical, said Dr Alexander Kuruvilla, chief health strategy officer, Practo. Read More...

June 20, 2023, After intimating the state drug regulator and to the district police chief, the Morigaon district drug regulator in Assam has given strict warning to the pharma wholesalers against breach of licence conditions and wanted them to correct all anomalies in the business for not being punished under Rule 65 of the Drug Act. Read More...

June 19, 2023, In order to make the licensing procedure in the drug control department flawless and transparent and the administration of the drugs control department more efficient, the director of the Tamil Nadu Drug Control Administration (TN DCA) has formed two supervisory committees to scrutinize all files and applications coming before the DC and the SLA in the department. Read More...

June 10, 2023, After dilly dallying for 40 days, the government of Tamil Nadu has finally decided to appoint a state licensing authority (SLA) in the department of drug control by giving additional charge to an Assist Drug Controller (ADC) in Kancheepuram district.Read More...

June 7, 2023, The Delhi High Court has recently directed the Central government to report the outcome of consultations and deliberations with the stakeholders related to the five-year-old draft notification for inclusion of rules to regulate online sale of drugs in six weeks, and inform the Court the final stand by the government on the matter. Earlier on December 12, 2018. Read More...

June 3, 2023, Bruhath Bengaluru Chemists and Druggists Association (BBCDA) is of the view that pharmacists today face unhealthy competition, long work hours and lack of recognition despite their qualification and ability to dispense information about medicines, adverse drug reactions and rational use of prescribed treatment protocols. Read More...

June 24, 2023, The Drugs Technical Advisory Board (DTAB) has recommended to get comments and inputs from Indian Council of Medical Research (ICMR) for further action on restricting Nicotine Replacement Therapies (NRTs) containing upto 2 mg or 4 mg only through prescription of authorised medical practitioners, as proposed by the Tobacco Control Division (TCD). Read More...

June 25, 2023, The National Health Service (NHS) stands as a cornerstone of healthcare in the United Kingdom, providing vital medical services to millions of individuals. However, an insidious and multifaceted threat now jeopardises its very existence. Read More...

June 23, 2023, Global pharma major Lupin Limited (Lupin) announced the launch of rufinamide oral suspension, 40 mg/mL to market a generic equivalent of Banzel oral suspension, 40 mg/mL of Eisai Inc. Read More...

June 23, 2023, The Karnataka drugs control department asserts that the NPPA’s Pharma Sahi Daam accelerates access to fair and reasonable prices of medicines. Read More...

June 22, 2023, Venus Remedies Limited, a leading research-based global pharmaceutical company, has achieved yet another landmark by securing marketing authorisation from Spain for meropenem, its highest selling generic product. The company, which has got this approval through its German subsidiary Venus Pharma GmbH for 500mg, 1g and 2g injections of this last-recourse antibiotic, happens to be the largest exporter of meropenem from India in the last three years. Read More...

June 22, 2023, The Medicines Control Agency (MCA), the national drug regulatory body of the West African nation the Gambia, is introducing a regulation of pre-shipment verification, inspection, quality testing and a clean report from a designated agency for pharmaceuticals from India to address issues related to substandard and falsified or counterfeit medicines entering the country, mandatory from July 1, 2023. Read More...

Global pharma major Lupin Limited (Lupin) announced the launch of rufinamide oral suspension, 40 mg/mL to market a generic equivalent of Banzel oral suspension, 40 mg/mL of Eisai Inc.
 
Rufinamide oral suspension had estimated annual sales of USD 72 million in the US (IQVIA MAT April 2023).
 
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.Read More...

June 9, 2023, There has been a significant increase in the complexity of pharma supply logistics in the recent years. The Covid pandemic further augmented that complexity in managing pharmaceuticals going by the raw material distribution and scattered manufacturing across the globe. The coordination across all these touch points is what makes pharma supply chain entirely complex, he added. Read More...

June 2, 2023, At a recently concluded roundtable organized by Consumer VOICE, a New Delhi-based consumer organization, senior MPs, top doctors leading medical institutions among others emphasized that multi-stakeholder and mission-mode action will be required to meet this critical health goal in the next two years.. Read More...

Vaccines, while generally safe, can have some common side effects that are usually mild and temporary. These may include pain, redness, or swelling at the injection site, low-grade fever, fatigue, headache, muscle or joint pain, and occasionally, nausea or vomiting. Serious side effects are rare, and vaccines undergo extensive testing to ensure their safety. Severe allergic reactions are extremely rare. It's important to consult a healthcare professional if you have any concerns about the side effects of vaccines. Read More...

June 17, 2023, Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to add positive data from the phase 3 VALOR-HCM study to the US Prescribing Information for Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules). Data added to the label showed that treatment with Camzyos significantly reduced the composite endpoint of guideline-based eligibility for septal reduction therapy (SRT) at Week 16 or the decision to proceed with SRT prior to or at Week 16. Read More...

June 22, 2023, The US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children 10 years and older with type 2 diabetes. These approvals provide a new class of medicines taken by mouth to treat paediatric type 2 diabetes. Metformin, the only other oral therapy available for the treatment of children with type 2 diabetes, was first approved for paediatric use in 2000.. Read More...

The Prescription has articles that make very good reading. Excellent presentation. Well done.

The Newsletter has extremely useful information for readers. Great reading, please continue.

Good newsletter which brings an array of Pharma News for the avid Prescription newsletter. Keep up the good work.

Dr. Anamika Wadhera 

BDS, MPH, MSW, MWMA

Director

Patient Safety And Access Initiative of India Foundation
B306, First Floor, C R Park, New Delhi -110019
jagograhakjago.com; www.jagograhakjago.com;
Disclaimer : Our newsletter endeavors to compile patient safety information from various sources . PSAIIF may not be held responsible for any article published in The Prescription.